...
首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF WARFARIN SODIUM 5 MILLIGRAMS TABLET IN HEALTY THAI SUBJECTS
【24h】

PHARMACOKINETICS AND BIOEQUIVALENCE STUDIES OF WARFARIN SODIUM 5 MILLIGRAMS TABLET IN HEALTY THAI SUBJECTS

机译:泰国健康人群中华法林钠5毫克片剂的药代动力学和生物等效性研究

获取原文
           

摘要

Objective: The present study aimed to evaluate the bioequivalence between the generic warfarin sodium tablet and a reference product when gave as equal labeled doses in healthy Thai subjects under fasting condition. Methods: A randomized, open-label, single dose, two treatments, two periods, two sequences, crossover design between 5 mg of warfarin administration under fasting condition was conducted in 22 male and female healthy Thai subjects. Each subject was assigned randomly to receive a single oral dose of the test formulation or the reference formulation of 5 mg warfarin tablets. Study periods were separated by a 14-day washout period. Blood samples were collected at 0.0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0, 2.5, 3.0, 4.0, 8.0, 12.0, 24.0, 36.0, 48.0 and 72.0 h after drug administration. A simple, sensitive and specific HPLC method was used for quantification of warfarin in plasma. Pharmacokinetic parameters were analyzed including C max , T max , t1/2 and AUC 0-72h . Results: Twenty subjects, selected randomly from healthy adult Thai subjects were enrolled, age of 22.5 + 3.1 years, weight, 59 + 6 kg. Twenty-one subjects completed both periods of the study. The mean C max values were 759.63 and 778.20 ng/ml and the mean AUC 0-72h were 20010.89 and 20418.55 ng. h./ml for test and reference formulations, respectively. The mean ratios for log-transformed data were 0.9955 and 0.9971 for C max , and AUC 0-72h , respectively. The 90% confidence intervals of the ratios of C max and AUC 0-72h between test and reference tablets were 88.23% – 105.70% and 94.40% – 99.61%. Conclusion: It can be concluded that test and reference warfarin 5 mg products were bioequivalent in terms of rate and extent of absorption. Keywords: Pharmacokinetic, Bioequivalence, Warfarin, HPLC, Validation, Human plasma.
机译:目的:本研究旨在评估在健康的泰国受试者在禁食条件下给予同等标记剂量的仿制华法林钠片与参考产品之间的生物等效性。方法:对22名健康的泰国男性和女性受试者进行了随机,开放标签,单剂量,两次治疗,两个周期,两个序列,在禁食条件下给予5 mg华法林的交叉设计。随机分配每位受试者以接受口服口服剂量的5毫克华法林片剂的测试制剂或参考制剂。研究期间隔为14天的淘汰期。给药后的0.0、0.25、0.5、0.75、1.0、1.25、1.5、2.0、2.5、3.0、4.0、8.0、12.0、24.0、36.0、48.0和72.0 h采集血样。一种简单,灵敏且特异的HPLC方法用于定量血浆中的华法林。分析了药动学参数,包括C max,T max,t1 / 2和AUC 0-72h。结果:从健康的成人泰国受试者中随机选择的20名受试者入选,年龄22.5 + 3.1岁,体重59 + 6公斤。 21名受试者完成了研究的两个阶段。平均C max值为759.63和778.20 ng / ml,平均AUC 0-72h为20010.89和20418.55 ng。 h./ml分别用于测试和参考配方。 C max和AUC 0-72h的对数转换数据的平均比分别为0.9955和0.9971。试验片剂和参考片剂之间的C max和AUC 0-72h之比的90%置信区间为88.23%– 105.70%和94.40%– 99.61%。结论:可以得出结论,测试和参比华法林5 mg产品在吸收速率和吸收程度方面具有生物等效性。关键字:药代动力学,生物等效性,华法林,HPLC,验证,人体血浆。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号